Rapidly progressive glomerulonephritis risk factors

Revision as of 18:23, 23 May 2018 by Aelsaiey (talk | contribs)
Jump to navigation Jump to search

Rapidly progressive glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rapidly progressive glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray Findings

CT-scan Findings

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rapidly progressive glomerulonephritis risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rapidly progressive glomerulonephritis risk factors

CDC on Rapidly progressive glomerulonephritis risk factors

Rapidly progressive glomerulonephritis risk factors in the news

Blogs on Rapidly progressive glomerulonephritis risk factors

Directions to Hospitals Treating Rapidly progressive glomerulonephritis

Risk calculators and risk factors for Rapidly progressive glomerulonephritis risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

Common risk factors in the development of rapidly progressive glomerulonephritis may be occupational, environmental, genetic, and viral. However, we don't know what causes the antibodies to form.

Risk Factors

Common risk factors in the development of rapidly progressive glomerulonephritis may be occupational, environmental, genetic, and viral. [1][2]

References

  1. Hellmark T, Segelmark M (2014). "Diagnosis and classification of Goodpasture's disease (anti-GBM)". J Autoimmun. 48-49: 108–12. doi:10.1016/j.jaut.2014.01.024. PMID 24456936.
  2. Bombassei GJ, Kaplan AA (1992). "The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture's syndrome)". Am J Ind Med. 21 (2): 141–53. PMID 1536151.
  3. Zhao J, Cui Z, Yang R, Jia XY, Zhang Y, Zhao MH (2009). "Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity". Kidney Int. 76 (10): 1108–15. doi:10.1038/ki.2009.348. PMID 19741587.
  4. Couser WG (2016). "Pathogenesis and treatment of glomerulonephritis-an update". J Bras Nefrol. 38 (1): 107–22. doi:10.5935/0101-2800.20160016. PMID 27049372.
  5. Wilson CB, Dixon FJ (1973). "Anti-glomerular basement membrane antibody-induced glomerulonephritis". Kidney Int. 3 (2): 74–89. PMID 4571918.

Template:WH Template:WS